Probactive Biotech and Vietnamese organization Dalat Nuclear Research Institute are collaborating to develop cancer drugs that combine antitumor antibodies and radioactive compounds.
Probactive Biotech says that it has combined medical-grade iodine-131 and yttrium-90 with antitumor antibodies, producing targeted anticancer activity.
Parts of the R&D program will be completed at the Dalat Nuclear Research Institute. Clinical trials will be conducted in Vietnam under the regulatory guidelines of the Ministry of Health and also in compliance with FDA regulations.